Cargando…
Tri-partite complex for axonal transport drug delivery achieves pharmacological effect
BACKGROUND: Targeted delivery of pharmaceutical agents into selected populations of CNS (Central Nervous System) neurons is an extremely compelling goal. Currently, systemic methods are generally used for delivery of pain medications, anti-virals for treatment of dermatomal infections, anti-spasmodi...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837052/ https://www.ncbi.nlm.nih.gov/pubmed/20085661 http://dx.doi.org/10.1186/1471-2202-11-8 |
_version_ | 1782178769027465216 |
---|---|
author | Filler, Aaron G Whiteside, Garth T Bacon, Mark Frederickson, Martyn Howe, Franklyn A Rabinowitz, Miri D Sokoloff, Alan J Deacon, Terrence W Abell, Chris Munglani, Raj Griffiths, John R Bell, B Anthony Lever, Andrew ML |
author_facet | Filler, Aaron G Whiteside, Garth T Bacon, Mark Frederickson, Martyn Howe, Franklyn A Rabinowitz, Miri D Sokoloff, Alan J Deacon, Terrence W Abell, Chris Munglani, Raj Griffiths, John R Bell, B Anthony Lever, Andrew ML |
author_sort | Filler, Aaron G |
collection | PubMed |
description | BACKGROUND: Targeted delivery of pharmaceutical agents into selected populations of CNS (Central Nervous System) neurons is an extremely compelling goal. Currently, systemic methods are generally used for delivery of pain medications, anti-virals for treatment of dermatomal infections, anti-spasmodics, and neuroprotectants. Systemic side effects or undesirable effects on parts of the CNS that are not involved in the pathology limit efficacy and limit clinical utility for many classes of pharmaceuticals. Axonal transport from the periphery offers a possible selective route, but there has been little progress towards design of agents that can accomplish targeted delivery via this intraneural route. To achieve this goal, we developed a tripartite molecular construction concept involving an axonal transport facilitator molecule, a polymer linker, and a large number of drug molecules conjugated to the linker, then sought to evaluate its neurobiology and pharmacological behavior. RESULTS: We developed chemical synthesis methodologies for assembling these tripartite complexes using a variety of axonal transport facilitators including nerve growth factor, wheat germ agglutinin, and synthetic facilitators derived from phage display work. Loading of up to 100 drug molecules per complex was achieved. Conjugation methods were used that allowed the drugs to be released in active form inside the cell body after transport. Intramuscular and intradermal injection proved effective for introducing pharmacologically effective doses into selected populations of CNS neurons. Pharmacological efficacy with gabapentin in a paw withdrawal latency model revealed a ten fold increase in half life and a 300 fold decrease in necessary dose relative to systemic administration for gabapentin when the drug was delivered by axonal transport using the tripartite vehicle. CONCLUSION: Specific targeting of selected subpopulations of CNS neurons for drug delivery by axonal transport holds great promise. The data shown here provide a basic framework for the intraneural pharmacology of this tripartite complex. The pharmacologically efficacious drug delivery demonstrated here verify the fundamental feasibility of using axonal transport for targeted drug delivery. |
format | Text |
id | pubmed-2837052 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-28370522010-03-12 Tri-partite complex for axonal transport drug delivery achieves pharmacological effect Filler, Aaron G Whiteside, Garth T Bacon, Mark Frederickson, Martyn Howe, Franklyn A Rabinowitz, Miri D Sokoloff, Alan J Deacon, Terrence W Abell, Chris Munglani, Raj Griffiths, John R Bell, B Anthony Lever, Andrew ML BMC Neurosci Research article BACKGROUND: Targeted delivery of pharmaceutical agents into selected populations of CNS (Central Nervous System) neurons is an extremely compelling goal. Currently, systemic methods are generally used for delivery of pain medications, anti-virals for treatment of dermatomal infections, anti-spasmodics, and neuroprotectants. Systemic side effects or undesirable effects on parts of the CNS that are not involved in the pathology limit efficacy and limit clinical utility for many classes of pharmaceuticals. Axonal transport from the periphery offers a possible selective route, but there has been little progress towards design of agents that can accomplish targeted delivery via this intraneural route. To achieve this goal, we developed a tripartite molecular construction concept involving an axonal transport facilitator molecule, a polymer linker, and a large number of drug molecules conjugated to the linker, then sought to evaluate its neurobiology and pharmacological behavior. RESULTS: We developed chemical synthesis methodologies for assembling these tripartite complexes using a variety of axonal transport facilitators including nerve growth factor, wheat germ agglutinin, and synthetic facilitators derived from phage display work. Loading of up to 100 drug molecules per complex was achieved. Conjugation methods were used that allowed the drugs to be released in active form inside the cell body after transport. Intramuscular and intradermal injection proved effective for introducing pharmacologically effective doses into selected populations of CNS neurons. Pharmacological efficacy with gabapentin in a paw withdrawal latency model revealed a ten fold increase in half life and a 300 fold decrease in necessary dose relative to systemic administration for gabapentin when the drug was delivered by axonal transport using the tripartite vehicle. CONCLUSION: Specific targeting of selected subpopulations of CNS neurons for drug delivery by axonal transport holds great promise. The data shown here provide a basic framework for the intraneural pharmacology of this tripartite complex. The pharmacologically efficacious drug delivery demonstrated here verify the fundamental feasibility of using axonal transport for targeted drug delivery. BioMed Central 2010-01-20 /pmc/articles/PMC2837052/ /pubmed/20085661 http://dx.doi.org/10.1186/1471-2202-11-8 Text en Copyright ©2010 Filler et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research article Filler, Aaron G Whiteside, Garth T Bacon, Mark Frederickson, Martyn Howe, Franklyn A Rabinowitz, Miri D Sokoloff, Alan J Deacon, Terrence W Abell, Chris Munglani, Raj Griffiths, John R Bell, B Anthony Lever, Andrew ML Tri-partite complex for axonal transport drug delivery achieves pharmacological effect |
title | Tri-partite complex for axonal transport drug delivery achieves pharmacological effect |
title_full | Tri-partite complex for axonal transport drug delivery achieves pharmacological effect |
title_fullStr | Tri-partite complex for axonal transport drug delivery achieves pharmacological effect |
title_full_unstemmed | Tri-partite complex for axonal transport drug delivery achieves pharmacological effect |
title_short | Tri-partite complex for axonal transport drug delivery achieves pharmacological effect |
title_sort | tri-partite complex for axonal transport drug delivery achieves pharmacological effect |
topic | Research article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2837052/ https://www.ncbi.nlm.nih.gov/pubmed/20085661 http://dx.doi.org/10.1186/1471-2202-11-8 |
work_keys_str_mv | AT filleraarong tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect AT whitesidegartht tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect AT baconmark tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect AT fredericksonmartyn tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect AT howefranklyna tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect AT rabinowitzmirid tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect AT sokoloffalanj tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect AT deaconterrencew tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect AT abellchris tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect AT munglaniraj tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect AT griffithsjohnr tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect AT bellbanthony tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect AT leverandrewml tripartitecomplexforaxonaltransportdrugdeliveryachievespharmacologicaleffect |